Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) have earned a consensus rating of “Hold” from the eight ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $7.33.
Several research firms recently commented on JSPR. William Blair assumed coverage on shares of Jasper Therapeutics in a research note on Wednesday, October 14th. They set an “outperform” rating on the stock. Wall Street Zen cut shares of Jasper Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Piper Sandler started coverage on shares of Jasper Therapeutics in a research note on Wednesday, August 12th. They set an “overweight” rating and a $2.00 target price for the company. HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th.
Read Our Latest Stock Analysis on JSPR
Jasper Therapeutics Trading Down 0.5%
Shares of JSPR stock opened at $0.48 on Tuesday. Jasper Therapeutics has a 12 month low of $0.32 and a 12 month high of $2.69. The stock has a market cap of $15.89 million, a PE ratio of -0.30 and a beta of 3.16. The company’s fifty day moving average price is $0.65 and its 200-day moving average price is $0.69.
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. On average, sell-side analysts forecast that Jasper Therapeutics will post -0.94 earnings per share for the current fiscal year.
About Jasper Therapeutics
Jasper Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for diseases involving the hematopoietic system, including conditions that require the replacement or modification of blood-forming stem cells. The company’s approach is designed to address biological barriers that can limit stem-cell transplantation, gene therapy and the treatment of mast cell–driven diseases.
Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody that targets CD117, a receptor found on hematopoietic stem cells and mast cells.
Featured Articles
- Five stocks we like better than Jasper Therapeutics
- 4 Stocks With Demand So Sticky That the AI Sell-Off Barely Touched Them at All
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
